These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6247049)

  • 21. Further immunological evidence for the presence of Fc receptors on the surface of HSV-infected cells.
    Ghyka G; Gologan R
    Virologie; 1976; 27(4):239-43. PubMed ID: 188233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus.
    Shore SL; Black CM; Melewicz FM; Wood PA; Nahmias AJ
    J Immunol; 1976 Jan; 116(1):194-201. PubMed ID: 173757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in antigenic properties of Fc-binding activity during infection with herpes simplex virus type 1.
    Welling-Wester S; Vos J; Wilterdink JB
    Arch Virol; 1984; 80(2-3):183-93. PubMed ID: 6202279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Demonstration of a receptor for IgG in Syrian hamster cells transformed with herpes simplex virus.
    Westmoreland D; Watkins JF; Rapp F
    J Gen Virol; 1974 Oct; 25(1):167-70. PubMed ID: 4372314
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunological basis for latency, recurrences and putative oncogenicity of herpes simplex virus.
    Lehner T; Wilton JM; Shillitoe EJ
    Lancet; 1975 Jul; 2(7924):60-2. PubMed ID: 49654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of herpes simplex virus growth caused by preparations of animal immunoglobulins is not dependent on Fc-Fc receptor interactions.
    Johansson PJ; Kjellén L
    Intervirology; 1988; 29(6):334-8. PubMed ID: 2466016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune inhibition of virus release from herpes simplex virus-infected cells.
    Skinner GR; Mushi EZ; Whitney JE
    Intervirology; 1975-1976; 6(4-5):296-308. PubMed ID: 186438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of the Fc receptor induced by herpes simplex virus.
    Costa J; Yee C; Nakamura Y; Rabson A
    Intervirology; 1978; 10(1):32-9. PubMed ID: 75867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demonstration of high levels of cytolytic antibodies reactive with HSV-1 and HSV-2 infected cell membranes in sera of genital tumour patients.
    Roane PR; washington P
    IARC Sci Publ (1971); 1975; (11 Pt 2):299-305. PubMed ID: 191374
    [No Abstract]   [Full Text] [Related]  

  • 31. Persistent infection of BHK cells with herpes simplex virus types 1 and 2 in the absence of specific anti-herpetic antibody.
    Szántó J; Lesso J; Lackovic V
    Acta Virol; 1976 Feb; 20(1):40-7. PubMed ID: 7939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electrokinetic alteration of the surface of herpes simplex virus infected cells.
    Thompson CJ; Docherty JJ; Boltz RC; Gaines RA; Todd P
    J Gen Virol; 1978 Jun; 39(3):449-61. PubMed ID: 77892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
    Bishop GA; Marlin SD; Schwartz SA; Glorioso JC
    J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up studies on herpes simplex antibodies in the course of cervical cancer. II. Antibodies to surface antigen of Herpes simplex virus infected cells.
    Christenson B; Espmark A
    Int J Cancer; 1976 Mar; 17(3):318-25. PubMed ID: 176115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of cell-to-cell spread of herpes simplex virus by leukocytes.
    Lodmell DL; Niwa A; Hayashi K; Notkins AL
    J Exp Med; 1973 Mar; 137(3):706-20. PubMed ID: 4347596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for herpes simplex virus type-selective receptors on cellular plasma membranes.
    Vahlne A; Svennerholm B; Lycke E
    J Gen Virol; 1979 Jul; 44(1):217-25. PubMed ID: 227992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Herpes simplex vaccine using cell membrane associated antigen in an animal model.
    Thornton B; Griffiths JB; Walkland A
    Dev Biol Stand; 1981; 50():201-6. PubMed ID: 6281105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Galactose-rich glycoproteins are on the cell surface of herpes virus-infected cells. 1. Surface labeling and serial lectin binding studies of Asn-linked oligosaccharides of glycoprotein gC.
    Kumarasamy R; Blough HA
    Arch Biochem Biophys; 1985 Feb; 236(2):593-602. PubMed ID: 2982317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycoproteins with type common and type specific antigenic sites excreted from cells infected with herpes simplex virus types 1 and 2.
    Randall RE; Killington RA; Watson DH
    J Gen Virol; 1980 Jun; 48(Pt 2):297-310. PubMed ID: 6156995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of herpes simplex virus type 1-induced Fc receptor in its interaction with rabbit immunoglobulin G (IgG).
    Johansson PJ; Blomberg J
    APMIS; 1990 Aug; 98(8):685-94. PubMed ID: 2169770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.